Orphan drug development is not taking off.
作者信息
Joppi Roberta, Bertele Vittorio, Garattini Silvio
出版信息
Br J Clin Pharmacol. 2009 May;67(5):494-502. doi: 10.1111/j.1365-2125.2009.03369.x. Epub 2009 Jan 21.
Abstract
摘要
相似文献
1
Orphan drug development is not taking off.
Br J Clin Pharmacol. 2009 May;67(5):494-502. doi: 10.1111/j.1365-2125.2009.03369.x. Epub 2009 Jan 21.
2
Orphan economics: the downside of supplyside pharmacology.
Ann Neurol. 2008 Sep;64(3):A13-6. doi: 10.1002/ana.21432.
3
The Orphan Drug Act: how well is it working?
Am Pharm. 1985 Sep;NS25(9):52-4. doi: 10.1016/s0160-3450(16)32834-3.
4
March on, not in.
Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515.
5
New products highlight ambiguity of orphan drug law.
Nat Biotechnol. 2003 Jan;21(1):6-7. doi: 10.1038/nbt0103-6b.
6
[Effectivity of data obtention previous to drug commercialization: utopy or reality?].
Med Clin (Barc). 2006 Nov 18;127(19):736-7. doi: 10.1157/13095534.
7
China's counterfeit medicine trade booming.
CMAJ. 2009 Nov 10;181(10):E237-8. doi: 10.1503/cmaj.109-3070. Epub 2009 Oct 5.
8
The Orphan Products Board of the Department of Health & Human Services.
Prog Clin Biol Res. 1985;197:19-23.
9
[Pharmacotherapy between theory and practice].
Ned Tijdschr Geneeskd. 1995 Nov 11;139(45):2295-6.
10
Adoption agent.
Minn Med. 2005 Mar;88(3):8-9.
引用本文的文献
1
Pivotal Studies for Drugs About to Be Launched for Rare Diseases: Will They Better Support Health Technology Assessment and Market Access than in the Past?
J Mark Access Health Policy. 2025 Jul 25;13(3):37. doi: 10.3390/jmahp13030037. eCollection 2025 Sep.
2
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.
Br J Clin Pharmacol. 2025 Apr;91(4):1084-1087. doi: 10.1002/bcp.70013. Epub 2025 Feb 16.
3
Pharmaceutical policy and innovation for rare diseases: A narrative review.
F1000Res. 2023 Nov 13;12:211. doi: 10.12688/f1000research.130809.2. eCollection 2023.
4
Implementation status of pharmacological studies in the development of orphan drugs.
Orphanet J Rare Dis. 2024 Jan 2;19(1):5. doi: 10.1186/s13023-023-03000-0.
5
Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan.
F1000Res. 2023 Nov 13;12:741. doi: 10.12688/f1000research.130388.1. eCollection 2023.
6
Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022.
Front Pharmacol. 2023 Mar 8;14:1138996. doi: 10.3389/fphar.2023.1138996. eCollection 2023.
7
Making Sure That Orphan Incentives Tip the Right Way in Europe.
Healthcare (Basel). 2022 Aug 23;10(9):1600. doi: 10.3390/healthcare10091600.
8
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21.
9
Ultra-rare disease: an European perspective.
Eur Respir Rev. 2020 Jul 3;29(156). doi: 10.1183/16000617.0195-2020. Print 2020 Jun 30.
10
Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.
PLoS One. 2018 Apr 3;13(4):e0194494. doi: 10.1371/journal.pone.0194494. eCollection 2018.
本文引用的文献
1
Clinical trials of orphan medicines.
Lancet. 2008 Jun 14;371(9629):2051-5. doi: 10.1016/S0140-6736(08)60876-4.
2
Why rare diseases are an important medical and social issue.
Lancet. 2008 Jun 14;371(9629):2039-41. doi: 10.1016/S0140-6736(08)60872-7.
3
Rare diseases: what's next?
Lancet. 2008 Jun 14;371(9629):1978-9. doi: 10.1016/S0140-6736(08)60847-8.
4
Predictors of orphan drug approval in the European Union.
Eur J Clin Pharmacol. 2008 May;64(5):545-52. doi: 10.1007/s00228-007-0454-6. Epub 2008 Jan 22.
5
Orphan drug development is progressing too slowly.
Br J Clin Pharmacol. 2006 Mar;61(3):355-60. doi: 10.1111/j.1365-2125.2006.02579.x.
6
Rare diseases and orphan drugs.
Br J Clin Pharmacol. 2006 Mar;61(3):243-5. doi: 10.1111/j.1365-2125.2006.02617.x.
Zotero 插件